Tekmira's Partner Presents New Clinical Data for LNP-Enabled Patisiran (ALN-TTR02)
28 avr. 2014 18h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 28, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported...
Tekmira Presents Advances in Anti-Viral Product Platform at Scientific Symposium
01 avr. 2014 10h25 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, April 1, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Announces Completion of Underwritten Public Offering of Common Stock
18 mars 2014 13h53 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 18, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Announces Pricing of Underwritten Public Offering of Common Stock
13 mars 2014 07h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 13, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Announces Proposed Public Offering of Common Stock
10 mars 2014 16h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 10, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today...
Tekmira Provides Corporate Update and Announces Year-End 2013 Results
06 mars 2014 07h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 6, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...
Tekmira Receives Fast Track Designation From FDA for Its Anti-Ebola Viral Therapeutic
05 mars 2014 16h05 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 5, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Conference Call and Webcast Advisory: Corporate Update and 2013 Year-End Financial Results
04 mars 2014 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, March 4, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that...
Tekmira Presents Recent Advances in mRNA Delivery at Scientific Symposium
25 févr. 2014 02h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 25, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA therapeutics, announced that recent advances in...
Tekmira Announces Filing of Shelf Prospectus and Registration Statement
21 févr. 2014 14h54 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Feb. 21, 2014 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a developer of RNA interference (RNAi) therapeutics, today announced that it...